KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) EBITDA Margin (2016 - 2026)

Fulgent Genetics' EBITDA Margin history spans 12 years, with the latest figure at 48.67% for Q1 2026.

  • On a quarterly basis, EBITDA Margin fell 2172.0% to 48.67% in Q1 2026 year-over-year; TTM through Mar 2026 was 29.56%, a 497.0% decrease, with the full-year FY2025 number at 4.56%, up 2152.0% from a year prior.
  • EBITDA Margin hit 48.67% in Q1 2026 for Fulgent Genetics, up from 125.0% in the prior quarter.
  • Over the last five years, EBITDA Margin for FLGT hit a ceiling of 63.05% in Q1 2022 and a floor of 214.34% in Q4 2023.
  • Historically, EBITDA Margin has averaged 34.72% across 5 years, with a median of 25.36% in 2024.
  • Biggest five-year swings in EBITDA Margin: soared 19317bps in 2024 and later crashed -10383bps in 2025.
  • Tracing FLGT's EBITDA Margin over 5 years: stood at 0.33% in 2022, then tumbled by -64436bps to 214.34% in 2023, then soared by 90bps to 21.17% in 2024, then tumbled by -490bps to 125.0% in 2025, then skyrocketed by 61bps to 48.67% in 2026.
  • Business Quant data shows EBITDA Margin for FLGT at 48.67% in Q1 2026, 125.0% in Q4 2025, and 18.26% in Q3 2025.